重组抗人CD4单抗(13B8.2)流式 | Syd Labs PA007415.m1
重组抗人CD4单克隆抗体，小鼠IgG1 Kappa（克隆号13B8.2，Syd Labs货号：PA007415.m1）是用哺乳动物细胞生产的重组抗体，适用于流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）等研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007415.m1 |
|---|---|
| 产品名称 | 重组抗人CD4单抗(13B8.2)流式 | Syd Labs PA007415.m1 |
| 英文名 | Non-conjugated Recombinant Anti-human CD4 Monoclonal Antibody (Clone: 13B8.2), Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇4，leu-3，T4 |
| 概述 | Syd Labs提供重组小鼠IgG1同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 13B8.2 |
| 同种型 | 小鼠 IgG1 kappa |
| 特异性 | 该重组 13B8.2 抗体与人CD4 特异性结合 |
| 免疫源 | 抗人CD4单克隆抗体（克隆：13B8.2）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 非偶联重组抗人CD4单克隆抗体，小鼠 IgG1 Kappa(克隆号13B8.2)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007415.m1 Syd Labs提供重组小鼠IgG1同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
抗人CD4单克隆抗体(克隆号13B8.2)，非偶联重组，小鼠IgG1 Kappa（Non-conjugated Recombinant Anti-human CD4 Monoclonal Antibody (Clone: 13B8.2), Mouse IgG1 Kappa，货号：PA007415.m1 Syd Labs）
重组13B8.2抗体可结合人CD4蛋白（分化群4）。CD4是一种糖蛋白，也是T细胞受体（TCR）的共受体。CD4蛋白表达于多种免疫细胞表面，包括辅助性T细胞、单核细胞、巨噬细胞和树突状细胞。
抗人CD4单抗(13B8.2)部分参考文献:
1. In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas
Troadec, S., et al. J Immunother. 2007 Feb-Mar;30(2):190-202. doi: 10.1097/01.cji.0000211333.15392.35
“The chimeric recombinant anti-CD4 antibody 13B8.2, expressed in baculovirus, was tested for antitumoral activity against T-cell lymphomas using flow cytometry. The 13B8.2 antibody induced apoptosis in CD4+ Jurkat cells, as confirmed by Annexin V staining, and significantly reduced CD4+ T cells in treated lymphoma cell lines. Cell viability was assessed after 48 hours using MTT assays, and the efficacy of 13B8.2 was compared with other anti-CD4 antibodies in vitro.”
2. An anti-CD4 (CDR3-loop) monoclonal antibody inhibits human immunodeficiency virus type 1 envelope glycoprotein-induced apoptosis
Guillerm, C., et al. Virology. 1998 Sep 15;248(2):254-63. doi: 10.1006/viro.1998.9298
“The anti-CD4 monoclonal antibody 13B8.2, targeting the CDR3-like region of CD4, was used to assess HIV-1 envelope glycoprotein-induced apoptosis via flow cytometry. Preincubation with 13B8.2 significantly reduced apoptosis in HIV-1-infected T cells and blocked CD4 crosslinking by gp120. The study also demonstrated that 13B8.2 inhibits syncytium formation in vitro, with cell surface CD4 expression quantified using fluorescently labeled antibodies.”
3. The Cytoplasmic Tail of CD4 Is Required for Inhibition of HIV-1 Env-Mediated Cell Fusion
Albright, C. A., et al. J Virol. 1997 Jun;71(6):4686-91. doi: 10.1128/JVI.71.6.4686-4691.1997
“The 13B8.2 antibody (anti-human CD4 antibody) was used to detect CD4 expression on transfected HeLa cells by flow cytometry to study HIV-1 envelope-mediated cell fusion. Mutations in the CD4 cytoplasmic tail abolished the inhibitory effect on cell fusion, while flow cytometry confirmed that CD4 surface expression remained unchanged. HIV-1 envelope glycoprotein binding was assessed through co-culture experiments.”
4. CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4
Benkirane, M., et al. J Virol. 1995 Nov;69(11):6904-10. doi: 10.1128/JVI.69.11.6904-6910.1995
“The anti-CD4 antibody 13B8.2, targeting the immunoglobulin CDR3-like region, was used to inhibit HIV-1 replication in Jurkat cells, with CD4 expression monitored by flow cytometry. The 13B8.2 antibody effectively blocked HIV-1 provirus transcription without significantly altering CD4 surface levels. Inhibition of HIV-1 entry was confirmed using syncytium formation assays.”
5. An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells
Benkirane, M., et al. EMBO J. 1993 Dec;12(12):4909-21. doi: 10.1002/j.1460-2075.1993.tb06182.x
“The 13B8.2 antibody (anti-human CD4 mAb), targeting the immunoglobulin CDR3-like region of CD4, was used to inhibit provirus transcription in HIV-1-infected Jurkat cells, with CD4 expression quantified by flow cytometry. The study showed that 13B8.2 does not affect HIV-1 entry but targets post-entry events, with stable CD4 expression confirmed during treatment.”